Please assess the completion status of the following clinical trial:

Trial Title: Impact of Ticagrelor Re-load on Pharmacodynamic Profiles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a clinical indication to be on ticagrelor therapy (90mg/bid)~2. On treatment with ticagrelor 90mg twice daily for at least 14 days~3. Age between 18 to 80 years~4. On aspirin \<100mg/day~Exclusion Criteria:~1. History of intracranial bleeding~2. Severe hepatic impairment (ALT \>2.5 times the upper limit of normal)~3. Active bleeding or propensity to bleed~4. Recent antiplatelet treatment (\< 14 days) with a glycoprotein IIb/IIIa antagonist~6. Platelet count \<80x106/mL 7. Hemodynamic instability 8. Serum creatinine \<30 mL/min 9. On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban) 10. Patients with sick sinus syndrome or II or III degree AV block without pacemaker protection 12. Drugs interfering CYP3A4 metabolism (to avoid interaction with Ticagrelor): ketoconazole, itraconazole, voriconazole, clarithromicin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromizycin 13. Hemoglobin \< 10g/dL 14. Pregnant females \[women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study\].

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor 180mg (Type: EXPERIMENTAL): Patients randomized to this arm will be administered 180 mg of ticagrelor (experimental arm, loading dose).
- Ticagrelor 90mg (Type: ACTIVE_COMPARATOR): Patients randomized to this arm will be administered 90 mg dose of ticagrelor (active comparator, standard dose).

Based on this trial design, predict the completion outcome and termination type (if applicable).